Alex B. Chebl (@AlexChebl) profile picture
Detroit, MI
Joined October 2015
⁦@AmyLynnAho⁩ talking at 6th Detroit Stroke Conference about Navigating the Post-Stroke Journey, highlighting the Herculean effort and costs required by patients and their care givers in their recovery post stroke. A real hero! ⁦@HenryFordNeuro⁩ ⁦@RiadRmdn⁩
1
1
3
1,727
ARAMIS Open label RCT DAPT vs tPA in Chinese minor stroke (NIHSS<6): median NIHSS 2. DAPT non-inferior with lower risk of deterioration and lower bleeding events. Higher NIHSS may be better w tPA. This is big deal #ISC23 @HenryFordNeuro @OwaisAlsrouji @GhadaMohamedMD @aboulnourh
6
14
1,556
SELECT2 RCT for large core: median ASPECTS 4 and inf core 80cc. NNT for benefit of 4.94. OR 1.51 for benefit. sICH 0.6% vs 1.1%. #ISC23 @HenryFordNeuro @OwaisAlsrouji @GhadaMohamedMD @aboulnourh @WBrinjikji
1
4
748
ANGEL-ASPECT RCT of EVT for large core <24hrs: stop early for EFFICACY! Median ASPECTS 3 & inf vol 60-63cc. Benefit all subgroups. sICH 6.1% vs2.7%. No diff in mortality. Less sleep for us, less disability for pts #ISC23 @HenryFordNeuro @OwaisAlsrouji @GhadaMohamedMD @aboulnourh
2
9
1,111
CATIS2 RCT early or delayed BP control post AIS (without IVT or EVT) no diff in 90d mRS #ISC23 @HenryFordNeuro @stephanamayer @OwaisAlsrouji @GhadaMohamedMD @aboulnourh
1
1
584
BEST2 RCT of BP after successful EVT: BP<140 better than 160 or 180 reducing infarct volume with no harm and marginal mRS benefit. No diff in sICH. Tighter BP control may be better. #ISC23 @HenryFordNeuro @stephanamayer @OwaisAlsrouji @aboulnourh @WBrinjikji
2
4
8
2,050
LACI-2: open label Isosorbide or cilostazol or combination for lacunar stroke and dependency prevention. The combination appeared to be safe and reduced recurrence and dependency. More data needed @HenryFordNeuro @GhadaMohamedMD @OwaisAlsrouji @aboulnourh #ISC23
4
10
1,232
TRACE2: IV tPA vs TNK <4.5hrs without EVT. Non-inferiority confirmed without increase sICH. Combined with better LVO recan, supports time window for tPA is running out. #ISC23 @HenryFordNeuro @OwaisAlsrouji @GhadaMohamedMD @aboulnourh
2
263
Is this the first meaningfully + neuroprotectant trial? APRIL showed lower mortality, infarct vol, better outcomes with ApToll infusion+EVT #isc23 ⁦@HenryFordNeuro⁩ ⁦@OwaisAlsrouji⁩ ⁦@WBrinjikji⁩ ⁦@stephanamayer⁩ ⁦@GhadaMohamedMD⁩ ⁦@aboulnourh⁩
5
21
1,355
EVT for BA occl highly effective & assoc w (first time ever) reduced mortality in Veritas analysis of 4 RCT. If there is tissue at risk, disabling deficit and LVO then it doesn’t matter the circulation! #getclotout ⁦@AHAMeetings⁩ ⁦@HenryFordNeuro⁩ ⁦@WBrinjikji⁩
4
1
13
2,661
Andreas Charidimou just gave exceptional & informative talk on Dx & mgt. of Cerebral Amyloid Angiopathy- a frustratingly challenging cause of ICH #DetroitStroke2022 ⁦@HenryFordNeuro⁩ ⁦@OwaisAlsrouji⁩ ⁦@DaiWaiOlson⁩ ⁦@GhadaMohamedMD⁩
1
7
23
Truly honored to host Ajay Wakhloo as one of our keynote lectures on advances in cerebral aneurysm mgt. for Detroit Stroke Conference 2022. ⁦@HenryFordNeuro⁩ ⁦@SteveKalkanisMD⁩ ⁦@OwaisAlsrouji⁩ ⁦@Ammarjumah4⁩
3
18
Adieu to one of brightest residents I’ve ever trained @aboulnourh. He’s the future of stroke & neurointerventional. Off to @EmoryUniversity Stroke fellowship where I know he will shine 💪🏻 passion, inquisitiveness and determination. @HenryFordNeuro @GhadaMohamedMD @OwaisAlsrouji
6
2
2
86
Interesting subanalysis of HERMÈS collaboration. The very old (>85) have more mortality benefit from thrombectomy. #ISC22 @HenryFordNeuro @GhadaMohamedMD @aboulnourh @StrokeAHA_ASA @svinsociety @OwaisAlsrouji
1
8
2
46
Congrats Hassan Aboul Nour for receiving the 2021 SVIN Trainee Pilot Grant. It’s easy to mentor trainees of this caliber: driven, inquisitive, & scientifically rigorous. I expect this will be only the first of many awards to come. ⁦@HenryFordNeuro⁩ ⁦⁦@aboulnourh⁩
4
32